What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
His main research concerns Surgery, Anesthesia, Thrombosis, Venous thrombosis and Anticoagulant.
As part of one scientific family, Gary E. Raskob deals mainly with the area of Surgery, narrowing it down to issues related to the Internal medicine, and often Cardiology.
His work deals with themes such as Apixaban, Edoxaban, Knee replacement and Intention-to-treat analysis, which intersect with Anesthesia.
His Thrombosis research integrates issues from Warfarin, Randomized controlled trial, Partial thromboplastin time and Heparin.
His work carried out in the field of Venous thrombosis brings together such families of science as Deep vein and Intensive care medicine.
Gary E. Raskob focuses mostly in the field of Anticoagulant, narrowing it down to topics relating to Low molecular weight heparin and, in certain cases, Vitamin K antagonist.
His most cited work include:
- Oral rivaroxaban for symptomatic venous thromboembolism (2257 citations)
- Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (1720 citations)
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism (1648 citations)
What are the main themes of his work throughout his whole career to date?
Gary E. Raskob focuses on Surgery, Internal medicine, Thrombosis, Pulmonary embolism and Venous thrombosis.
Many of his studies on Surgery apply to Clinical trial as well.
Gary E. Raskob has researched Thrombosis in several fields, including Anesthesia, Randomized controlled trial, Heparin and Confidence interval.
The various areas that Gary E. Raskob examines in his Anesthesia study include Apixaban and Regimen.
His Pulmonary embolism study combines topics from a wide range of disciplines, such as Prospective cohort study, Lung, Radiology and Vitamin K antagonist.
His Venous thrombosis research incorporates themes from Idraparinux and D-dimer.
He most often published in these fields:
- Surgery (31.86%)
- Internal medicine (30.51%)
- Thrombosis (30.51%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (30.51%)
- Venous thromboembolism (19.66%)
- Cancer (9.15%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Venous thromboembolism, Cancer, Rivaroxaban and Thrombosis are his primary areas of study.
His work on Edoxaban, Confidence interval, Randomized controlled trial and Stroke as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His study explores the link between Edoxaban and topics such as Low molecular weight heparin that cross with problems in Anticoagulant therapy.
His Randomized controlled trial research is multidisciplinary, relying on both Anticoagulant, Anesthesia and Clinical trial.
Gary E. Raskob works in the field of Thrombosis, focusing on Deep vein in particular.
In Intensive care medicine, Gary E. Raskob works on issues like Apixaban, which are connected to Venous thrombosis.
Between 2017 and 2021, his most popular works were:
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (114 citations)
- Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. (65 citations)
- Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. (48 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Cancer
His primary areas of study are Internal medicine, Edoxaban, Rivaroxaban, Confidence interval and Randomized controlled trial.
His research on Edoxaban frequently connects to adjacent areas such as Anticoagulant.
His study in Anticoagulant is interdisciplinary in nature, drawing from both Vitamin K antagonist, Intensive care medicine, Dabigatran, Betrixaban and Apixaban.
The Rivaroxaban study combines topics in areas such as Relative risk and Placebo.
His specific area of interest is Thrombosis, where Gary E. Raskob studies Deep vein.
His Deep vein study incorporates themes from Anesthesia, Preoperative care, Arthroplasty, Venography and Pulmonary embolism.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
